Current membership charges are just £35 per year.
Choose from one, two or three years membership period at signup!
To organise at least one symposium per year To maintain a human resource directory To maintain a recommended reference/reading directory To facilitate research To be financially viable To liaise with other groups associated with care of patients with renal impairment To facilitate exchange of ideas and information To maintain an international perspective To facilitate training of pharmacists and other health care staff associated with care of patients with renal impairment To respond to educational and training requirements of membership as indicated by annual survey To maintain a renal drug file
This Medication Optimisation Toolkit can be used in conjunction with the ‘Acute Kidney Injury - Risk Assessment Proforma’ developed by the National AKI Delivery Group
We've added new online payment facilities, pay online for ease of use and continued website access
Member Profile Page
Are you unsure about dosing a particular drug on your renal unit or want to find out information on renal specific protocols? The UKRPG Q&A forum may be able to help. Post a question on the website, fellow renal pharmacists will be notified and may be able to answer your burning question.
Does anyone have any pathways that involve asking GPs to check bloods for patients on Tolvaptan homecare? We have one prescriber who isnt very reliable at doing monthly bloods and wants to draw up a pathway to ask GPs to check. I presume he would still be responsible for checking blood results ...
Hi For those of you who are not familiar with this, once a month we hold a teleconference session with a focus on discussing unanswered questions on the RPG Members Q&A board. The aim is to put our heads together and attempt to answer them as a group. One of the clinical subgroup will then post a ...
Hi. We have a renal transplant pt (good renal function) who has developed IBD. Renal team are keen to avoid anti-TNF alfa meds due to theoretical increased risk of rejection in SOT recipients. Gastro have asked about vedolizumab Sara has looked into it and cannot find anything specific that co ...